危险系数
医学
内科学
队列
胃肠病学
肾移植
肾病
置信区间
移植
肾脏疾病
肾小球肾炎
泌尿科
肾
糖尿病
内分泌学
作者
Nada Alachkar,Marco Delsante,Ross S. Greenberg,Abbal Koirala,Tarek Alhamad,Basmah Abdalla,Manish Anand,Ben Boonpheng,Christopher D. Blosser,Umberto Maggiore,Serena M. Bagnasco
出处
期刊:Transplantation
[Wolters Kluwer]
日期:2023-05-19
卷期号:107 (9): 2055-2063
被引量:12
标识
DOI:10.1097/tp.0000000000004640
摘要
BACKGROUND: The modified Oxford classification mesangial and endocapillary hypercellularity, segmental sclerosis, interstitial fibrosis/tubular atrophy, and the presence of crescents (MEST-C) of immunoglobulin A nephropathy (IgAN) was recently shown to be a predictor of graft failure in Asians with recurrent IgAN. We aimed to validate these findings in a cohort from North American centers participating in the Banff Recurrent Glomerulopathies Working Group. METHODS: We examined 171 transplant recipients with end-stage kidney disease because of IgAN; 100 of them with biopsy-proven recurrent IgAN (57 of them had complete MEST-C scores) and 71 with no recurrence. RESULTS: IgAN recurrence, which was associated with younger age at transplantation ( P = 0.012), strongly increased the risk of death-censored graft failure (adjusted hazard ratio, 5.10 [95% confidence interval (CI), 2.26-11.51]; P < 0.001). Higher MEST-C score sum was associated with death-censored graft failure (adjusted hazard ratio, 8.57 [95% CI, 1.23-59.85; P = 0.03] and 61.32 [95% CI, 4.82-779.89; P = 0.002] for score sums 2-3 and 4-5 versus 0, respectively), and so were the single components endocapillary hypercellularity, interstitial fibrosis/tubular atrophy, and crescents ( P < 0.05 each). Overall, most of the pooled adjusted hazard ratio estimates associated with each MEST-C component were consistent with those from the Asian cohort (heterogeneity I2 close to 0%, and P > 0.05). CONCLUSIONS: Our findings may validate the prognostic usefulness of the Oxford classification for recurrent IgAN and support the inclusion of the MEST-C score in allograft biopsies diagnostic reports.
科研通智能强力驱动
Strongly Powered by AbleSci AI